--- title: "Exploring Charles River's Earnings Expectations" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/276150034.md" description: "Charles River (NYSE:CRL) is set to announce its quarterly earnings on February 18, 2026, with analysts expecting an EPS of $2.34. Investors are eager for positive guidance following last quarter's EPS beat of $2.43, which led to a 1.9% share price increase. Currently, shares are trading at $161.35, down 3.63% over the past year. Analyst ratings suggest a consensus outlook, with an average one-year price target indicating potential growth. Market reactions will likely hinge on the guidance provided during the earnings release." datetime: "2026-02-17T17:01:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276150034.md) - [en](https://longbridge.com/en/news/276150034.md) - [zh-HK](https://longbridge.com/zh-HK/news/276150034.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/276150034.md) | [English](https://longbridge.com/en/news/276150034.md) # Exploring Charles River's Earnings Expectations Charles River (NYSE:CRL) is preparing to release its quarterly earnings on Wednesday, 2026-02-18. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Charles River to report an **earnings per share** (EPS) of $2.34. Anticipation surrounds Charles River's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter. New investors should understand that while earnings performance is important, market reactions are often driven by guidance. ### Earnings Track Record Last quarter the company beat EPS by $0.10, which was followed by a 1.9% increase in the share price the next day. Here's a look at Charles River's past performance and the resulting price change: **Quarter** **Q3 2025** **Q2 2025** **Q1 2025** **Q4 2024** **EPS Estimate** 2.33 2.50 2.09 2.53 **EPS Actual** 2.43 3.12 2.34 2.66 **Price Change %** 2.00 0.00 3.00 \-2.00 ![eps graph](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771347660_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) ### Tracking Charles River's Stock Performance Shares of Charles River were trading at $161.35 as of February 16. Over the last 52-week period, shares are down 3.63%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. ### Analyst Opinions on Charles River For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Charles River. Analysts have provided Charles River with ratings, resulting in a consensus rating of . The average one-year price target stands at $, suggesting a potential . To track all earnings releases for Charles River visit their earnings calendar on our site. _This article was generated by Benzinga's automated content engine and reviewed by an editor._ ### 相關股票 - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [iShares US Healthcare Providers (IHF.US)](https://longbridge.com/zh-HK/quote/IHF.US.md) - [Charles River Laboratorie (CRL.US)](https://longbridge.com/zh-HK/quote/CRL.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [iShares Genomics Immunology and Healthcare ETF (IDNA.US)](https://longbridge.com/zh-HK/quote/IDNA.US.md) ## 相關資訊與研究 - [Allworth Financial LP Reduces Holdings in Biodesix, Inc. $BDSX](https://longbridge.com/zh-HK/news/281318320.md) - [Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat](https://longbridge.com/zh-HK/news/281233412.md) - [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/zh-HK/news/281186075.md) - [Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Consensus Recommendation of "Hold" from Analysts](https://longbridge.com/zh-HK/news/281385092.md) - [Io Biotech Inc - Files Voluntary Chapter 7 Bankruptcy Petition On March 31, 2026 - SEC Filing](https://longbridge.com/zh-HK/news/281187506.md)